CNS Pharmaceuticals Q2 FY26 net loss widens 9% to $2.59 million year over year

• CNS Pharmaceuticals posted a net loss of $2.59 million for the quarter ended June 30, 2026, widening 9% year over year.
• Operating loss widened 12.1% to $2.7 million as total operating expenses climbed 12.1% to $2.7 million.
• General and administrative costs rose 20.7% to $1.5 million; research and development spending edged up 2.9% to $1.2 million.
• Interest income more than doubled to $116,000, lifting other income to $112,000; cash totaled $20 million at quarter-end.
• Strategy shift announced in March 2026 targets new development-stage assets, while exploring out-licensing of legacy TPI 287 and Berubicin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006224), on August 12, 2026, and is solely responsible for the information contained therein.